Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 473

Sort by

Sort Order Select

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Benjamin Watkins, Yvonne Suessmuth, Kayla Betz, BS, Alison Yu, PhD, Brandi Bratrude, Muna Qayed, MD MSc, Kathryn Pellegrini, Steven Bosinger, Amelia Langston, MD, John T. Horan, MDMPH, Bruce R. Blazar, MD, Leslie Kean, MD PhD

Blood (2019) 134 (Supplement_1): 596.

https://doi.org/10.1182/blood-2019-131955

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd

Joshua D Brandstadter, MD PhD, Eric Perkey, Brian T. Gaudette, PhD, Léolène Carrington, PhD, Daniela Gomez-Atria, PhD, Bruce R. Blazar, MD, Burkhard Ludewig, PhD, Anastasia Tikhonova, PhD, Iannis Aifantis, PhD, David Allman, PhD, Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): 588.

https://doi.org/10.1182/blood-2019-123533

Published: 2019

Journal Articles

Multiple Myeloma :Trends in Consulting Fees and Drug Utilization

Daniel Chakos, MD, Azam Farooqui, MD, Kimberly McCormick, Abhishek R Chilkulwar

Blood (2019) 134 (Supplement_1): 5823.

https://doi.org/10.1182/blood-2019-132036

Published: 2019

Journal Articles

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

Bishwas Shrestha, PhD, Kelly Walton, Jordan Reff, Elizabeth M. Sagatys, MD, Nhan Tu, PhD, Justin C. Boucher, PhD, Tayyeb Ghafoor, BS, Joseph Pidala, MD, Bruce R. Blazar, MD, Claudio Anasetti, MD, Brian C. Betts, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 196.

https://doi.org/10.1182/blood-2019-124031

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Victor A. Chow, MD, Paul S. Martin, MD, Stephen D. Smith, MD, Brian G. Till, MD, Solomon A. Graf, MD, Kerstin L. Edlefsen, MD, Lindsay M. Hannan, MD MSPH, Elahe A. Mostaghel, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5254.

https://doi.org/10.1182/blood-2019-125462

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Murtadha Al-Khabori, MD, Shoaib Al-Zadjali, PhD, Iman Al Noumani, Khalil Al Farsi, Salam Al-Kindi, MD, Mohamed Al Huneini, MD, Naglaa Fawaz, MBBChir, MMSc, PhD, Al Lamki Sulayma, MD, Mahdiya Pir Al Bulushi, MD FRCPC, Khalid Al Hashmi, MD, Muna Al Tarshi, MD, Muhanna Almusalhi

Blood (2019) 134 (Supplement_1): 5383.

https://doi.org/10.1182/blood-2019-128309

Published: 2019

Journal Articles

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Jordon Jaggers, Heidi D. Klepin, MD, Tanya M. Wildes, MD, Rebecca L. Olin, MD, Andrew S. Artz, MD, Sarah A Wall, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5819.

https://doi.org/10.1182/blood-2019-131504

Published: 2019

Journal Articles

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD

Danny W. Bruce, PhD, Oleg Kolupaev, PhD, Hemamalini Bommiasamy, PhD, Heather Stefanski, MD PhD, Bruce R. Blazar, MD, James M. Coghill, Jr., MD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3205.

https://doi.org/10.1182/blood-2019-126848

Published: 2019

Journal Articles

The Innate Immune Sensor Sting Promotes Donor CD8 + T Cell Activation and Recipient APC Death Early after Preclinical Allogeneic Hematopoietic Stem Cell Transplantation

Cameron S. Bader, BS, Henry Barreras, MPH, Casey O. Lightbourn, BS, MS, Sabrina N. Copsel, PhD, Dietlinde Wolf, PhD, Jingjing Meng, PhD, Jeonghyun Ahn, PhD, Krishna V Komanduri, MD, Bruce R. Blazar, MD, Lei Jin, PhD MSc, Glen N. Barber, PhD, Sabita Roy, PhD, Robert B. Levy, PhD

Blood (2019) 134 (Supplement_1): 3202.

https://doi.org/10.1182/blood-2019-130197

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Sarah Mirahsani, Kelda M. Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Mohamed L. Sorror, MD MSc, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 3824.

https://doi.org/10.1182/blood-2019-130834

Published: 2019

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Blood (2019) 134 (Supplement_1): 4026.

https://doi.org/10.1182/blood-2019-124116

Published: 2019

NARROW

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Dll1 and Dll4 Notch Ligands Prime T Cell Alloimmunity and Are Expressed in Non-Overlapping Populations of Fibroblastic Stromal Cells in Spleen and Lymph Nodes at the Onset of Gvhd

Multiple Myeloma :Trends in Consulting Fees and Drug Utilization

Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

A Window Study of Ixazomib in Untreated B-NHL

Overall Survival in Patients with JAK2 and ASXL1 Positive Myeloproliferative Neoplasms

Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD

The Innate Immune Sensor Sting Promotes Donor CD8 + T Cell Activation and Recipient APC Death Early after Preclinical Allogeneic Hematopoietic Stem Cell Transplantation

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only